Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results
News provided by
Share this article
Share this article
NEWARK, N.J., March 17, 2021 /PRNewswire/ Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.50 for the second quarter of its 2021 fiscal year, the three months ended January 31, 2021.
Q2 FY 2021 Consolidated Financial and Operational Highlights
Revenue of $1.0 million, generated by Rafael Holdings real estate portfolio, decreased from $1.2 million in the year-ago quarter due, in part, to the sale of its building in Piscataway, NJ.
Loss per share of $0.50 compared to a loss per share of $0.08 in the year ago quarter primarily due to a $7.0 million impairment of the company s interest in Altira, as described below.
Barer Institute Announces Licensing Agreement with Princeton University s Office of Technology Licensing for SHMT Inhibitor Program
News provided by
Share this article
Share this article
NEWARK, N.J., Dec. 22, 2020 /PRNewswire/ The Barer Institute, a cancer drug development initiative of Rafael Holdings, Inc., (NYSE: RFL), today announced that it has reached an agreement with Princeton University s Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz, in the Department of Chemistry, Princeton University, for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program and related intellectual property.
SHMT is critical source of 1–carbon units utilized in cellular nucleotide synthesis. SHMT isoforms are upregulated in numerous cancers and have been shown to be a valuable target for metabolic cancer treatment.
A cancer link to obesity: A metabolic tug-of-war
The Harvard Gazette
Obesity has been linked to increased risk for over a dozen different types of cancer, as well as worse prognosis and survival. Over the years, scientists have identified obesity-related processes that drive tumor growth, such as metabolic changes and chronic inflammation, but a detailed understanding of the interplay between obesity and cancer has remained elusive.
Now, in a study in mice, Harvard Medical School (HMS) researchers have uncovered a new piece of this puzzle, with surprising implications for cancer immunotherapy: Obesity allows cancer cells to outcompete tumor-killing immune cells in a battle for fuel.